Recommendations for the Management of Patients with Familial Hypercholesterolemia

Current Atherosclerosis Reports

Volumn 17, Issue 1, 2014, Pages

  Feldman, David I ^a,e   Blaha, Michael J ^a   Santos, Raul D ^b   Jones, Steve R ^a   Blumenthal, Roger S ^a   Toth, Peter P ^a,c   Sperling, Laurence S ^d   Martin, Seth S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CGH MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Assessment; Atherosclerosis; Diagnosis; Familial hypercholesterolemia; Guidelines; LDL; Screening; Treatment

Indexed keywords

ANTILIPEMIC AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; LIPID ANALYSIS; MALE; PHENOTYPE; PREGNANT WOMAN; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; RISK FACTOR; UNITED STATES; BLOOD; DISEASE MANAGEMENT; HYPERLIPOPROTEINEMIA TYPE II; PRACTICE GUIDELINE;

DISEASE MANAGEMENT; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; PRACTICE GUIDELINES AS TOPIC;

EID: 84938360400     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0473-6     Document Type: Review

References (54)

1. Santos RD, Maranhao RC. What is new with familial hypercholesterolemia? Curr Opin Lipidol. 2014;25:183–8. This article comprehensively reviews the underdiagnosed and high-risk nature of familial hypercholesterolemia. It also highlights the FH-associated subclinical disease and novel treatments that will take aim at reducing the burden of severely increased levels of cholesterol.
2. Benn W, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956–64.
3. Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935–47. In this state of the art paper, experts cover the clinical diagnosis, management, and emerging therapies that are associated with FH. They also recommend ways to efficiently utilize cascade screening and genetic testing to increase the detection of unknown cases of familial hypercholesterolemia.
4. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolemia: a case-control study. Lancet. 2013;381:1293–301. In this study, which genotyped for 12 common LDL-C-raising alleles in order to compare gene score distribution among different participants and controls, mutation negative patients were recognized to have significantly higher LDL-C scores. Also, in patients with FH, but no known mutation, a polygenic cause is considered, and cascade screening procedures should adjust accordingly.
5. Van Aalst-Cohen ES, Jansen AC, Tanck MW. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J. 2006;27:2240–6.
6. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S9–17.
7. Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol. 2010;22:422–9.
8. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolemia of the European Atherosclerosis Society. Eur Heart J. 2014.
9. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–8. This important review discussed the diagnostic criteria for HoFH, as defined in multiple studies. With an emphasis on the history of HoFH, this review covered the effectiveness of current therapy and the excitement surrounding future novel therapies.
10. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19(12):1043–60.
11. Miname MH, Santos RD. Imaging biomarkers to track subclinical atherosclerosis in heterozygous familial hypercholesterolemia. Clin Lipidol. 2013;8:1–12.
12. Stone NJ, Levy RI, Fredrickson DS. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476–88.
13. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969;2:1380–2.
14. Sprecher DL, Schaefer EJ, Kent KM, et al. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol. 1984;54:20–30.
15. Nordestgaard BG, Chapman M, Humphries SE. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90.
16. Pronovost PJ. Enhancing physicians use of clinical guidelines. JAMA. 2013;310:2501–2. This commentary on the importance of checklists convinced us to consolidate the current guidelines into a checklist that highlights FH recommendations.
17. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Int J Cardiol. 2014;171:309–25. This paper, led by an esteemed group of FH experts, covered the guidelines for detecting, screening, testing, and managing adults and children with familial hypercholesterolemia. Each guideline recommendation also covered the level of evidence and grades of recommendation.
18. Goldberg AC, Hopkins PN, Toth PP. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S1–8. This article provided expert US guidance on the expert recommendations for improving screening, detection, and treatment of both adults and children with familial hypercholesterolemia.
19. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011;128:S213.
20. Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:S30–7. With increased opportunity for improvement, children with FH require dedicated attention and evidence-guided recommendations. In this paper, FH experts consolidated a set of specific recommendations to help improve the prognoses and progression of children with familial hypercholesterolemia.
21. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ. 1991;303:893–6.
22. Austin MA, Hutter CM, Zimmern RL, Humprhies SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a huge prevalence review. Am J Epidemiol. 2004;160(5):407–20.
23. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171–6.
24. Stein EA, Raal FJ. Polygenic familial hypercholesterolemia: does it matter? Lancet. 2013;381:1255–7.
25. Versmissen J, Oosterveer DM, Yazdanpanah M. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
26. Bellanger N, Orsoni A, Julia Z, et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2011;31:1675–81.
27. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;63(25 Pt B):2889–934.
28. Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemia’s in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hyperchoelsterolemia. J Clin Lipidol. 2011;5:S38–45.
29. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90.
30. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92:1287–93.
31. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007–12.
32. Van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52:1421–9.
33. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal RJ. Effect of proprotein convertase subtillisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113–20.
34. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36.
35. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408–17.
36. Leebmann J, Roeseler E, Julius U, for the Pro(a)LiFe Study Group. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567–76.
37. Mehta PK, Baer J, Nell C, Sperling LS. Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. Curr Treat Option Cardiovasc Med. 2009;11:279–88.
38. Mabuchi H, Koizumi J, Chimizu M, et al. Long term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998;82:1489–95.
39. Braamskamp M, Langslet G, McCrindle BW, et al. Efficacy and safety of rosuvastatin in children aged 6–17 years with familial hypercholesterolemia: findings from the CHARON study. EAS 2014; Madrid, Spain. Abstract M140.
40. Braamskamp M, Langslet G, McCrindle BW, et al. Effect of rosuvastatin therapy on carotid intima media thickness in children with familial hypercholesterolemia: findings from the CHARON study. EAS 2014; Madrid, Spain.
41. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2014. doi:10.1093/eurheartj/ehu058.
42. Statistics Netherlands (in Dutch: Centraal Bureau voor de Statistiek). https://www.cbs.nl (31 October 2012).
43. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–68.
44. Eapen DJ, Valiani K, Reddy S, Sperling L. Management of familial hypercholesterolemia during pregnancy: case series and discussion. J Clin Lipidol. 2011;6:88–91.
45. Amunsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis. 2006;189:451–7.
46. Berge LN, Arnesen E, Forsdahl A. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet Gynecol Scand. 1996;75:439–42.
47. Kusters DM, Homsma SJM, Hutten BA, Twickler MTB, Avis HJ, van der Post JA, et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. Neth J Med. 2010;68:299–303.
48. Crouse JR. Hypertriglyceridemia: a contraindication for use of bile acid binding resins. Am J Med. 1987;83:243–8.
49. Kusters DM, Avis HJ, Braamskamp MJ, et al. Inheritance pattern of familial hypercholesterolemia and markers of cardiovascular risk. J Lipid Res. 2013;54:2543–9.
50. Van der Graaf A, Vissers MN, Gaudet D, et al. Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring. Arterioscler Thromb Vasc Biol. 2010;30:2673–7.
51. Napoli C, Glass CK, Witztum JL, et al. Influence of maternal hypercholesterolemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999;354:1234–41.
52. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familiar hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
53. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolemia: 2-year interim results of an open-label extension. Eur Heart J. 2013. doi:10.1093/eurheart/eht549.
54. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6.